1. Home
  2. ATON vs TOVX Comparison

ATON vs TOVX Comparison

Compare ATON & TOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo AlphaTON Capital Corp.

ATON

AlphaTON Capital Corp.

N/A

Current Price

$0.33

Market Cap

9.3M

Sector

Energy

ML Signal

N/A

TOVX

Theriva Biologics Inc.

HOLD

Current Price

$0.33

Market Cap

10.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ATON
TOVX
Founded
1973
2001
Country
British Virgin Islands
United States
Employees
4
N/A
Industry
Oil & Gas Production
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
9.3M
10.4M
IPO Year
N/A
2012

Fundamental Metrics

Financial Performance
Metric
ATON
TOVX
Price
$0.33
$0.33
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
1
Target Price
$2.00
$1.00
AVG Volume (30 Days)
763.1K
28.6M
Earning Date
07-24-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
89.07
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.28
$0.16
52 Week High
$13.80
$1.50

Technical Indicators

Market Signals
Indicator
ATON
TOVX
Relative Strength Index (RSI) 44.61 60.42
Support Level $0.28 $0.18
Resistance Level $0.35 $0.53
Average True Range (ATR) 0.03 0.04
MACD 0.01 0.01
Stochastic Oscillator 71.54 45.22

Price Performance

Historical Comparison
ATON
TOVX

About ATON AlphaTON Capital Corp.

AlphaTON Capital Corp is a specialized digital asset treasury company focused on building and managing a strategic reserve of TON tokens and developing the Telegram ecosystem. The company implements a comprehensive treasury strategy that combines direct token acquisition, validator operations, and strategic ecosystem investments to generate sustainable returns for shareholders. Through its operations, it provides public market investors with institutional-grade exposure to the TON ecosystem and Telegram's billion user platform.

About TOVX Theriva Biologics Inc.

Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.

Share on Social Networks: